You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞太藥業(002370.SZ):2019年度計提減值準備、確認投資損失合計18.38億元
格隆匯 02-25 19:55

格隆匯2月25日丨亞太藥業(002370.SZ)公佈,公司對2019年12月31日存在的可能發生減值跡象的資產,範圍包括其他應收賬款、存貨、固定資產、在建工程、開發支出、其他非流動資產等,進行全面清查和進行減值測試後,2019年度擬計提各項減值準備共計5.98億元。

因上海新高峯生物醫藥有限公司(“上海新高峯”)及其子公司無法恢復正常經營,公司本期對上海新高峯資產組進行測試,確認投資損失12.4億元。

綜上,公司此次計提減值準備、確認投資損失合計18.38億元。

根據《企業會計準則》、《公司章程》等相關規定,為真實反映公司財務狀況,公司對部分賬齡較長,預計無法收回的應收賬款進行清理,並予以核銷,此次核銷應收賬款848.86萬元。

此次計提減值準備、確認投資損失將減少公司2019年度淨利潤18.38億元,合併報表歸屬於母公司所有者權益將減少18.38億元。

公司此次核銷應收賬款848.86萬元,其中已按照賬齡計提減值準備為539.05萬元,本期發生壞賬損失309.81萬元,實際減少本期淨利潤309.81萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account